Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
Puma Biotech files for EU approval of neratinib in breast cancer
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Hobbling Along a Year After Neratinib's Launch – B4 U Consent
Puma Bio's neratinib shows incremental effect in certain HER2+ breast cancer patients in late-stage study; shares down 4% By Seeking Alpha
Puma Biotechnology: Neratinib Is Being Misunderstood (NASDAQ:PBYI) | Seeking Alpha
Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | FiercePharma
Neratinib - Wikipedia
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting | Business Wire
Puma Biotechnology
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS - boerse.de
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Puma Biotechnology
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug - ChemDiv
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer - ChemDiv
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China | Business Wire
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib) | PharmaShots
